Health
Keros Plunges After Dosing Halted in Lung Drug Trial on Safety
This article is for subscribers only.
Keros Therapeutics Inc. shares plunged after the biotech company halted dosing for some patients in a mid-stage trial of its lung disorder drug over side effect concerns.
Shares of Lexington, Massachusetts-based Keros dropped as much as 72% in trading before US markets opened Thursday. If the change holds into regular trading, it will wipe out nearly all gains the stock made this year through Wednesday’s close.